Neuronetics (STIM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on the stock and has a $8.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
William Plovanic has given his Buy rating due to a combination of factors including Neuronetics’ strong revenue performance and strategic initiatives. The company reported a significant increase in revenue for the first quarter, surpassing both Canaccord Genuity’s and consensus estimates, which indicates robust operational performance.
Additionally, Neuronetics has raised the lower end of its fiscal year 2025 revenue guidance, reflecting confidence in its growth trajectory. While there was a higher-than-expected cash burn, management is focused on achieving cash flow breakeven by the third quarter, with incentives in place to potentially reach this milestone earlier. The company’s strategic focus on expanding its NeuroStar TMS therapy and optimizing operations in Greenbrook centers further supports the positive outlook. Despite some concerns over cash burn, the overall financial and strategic position of Neuronetics justifies the Buy rating.
According to TipRanks, Plovanic is a 4-star analyst with an average return of 3.2% and a 44.97% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as TransMedics Group, Atricure, and Dexcom.